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Mutations in the PTEN induced putative kinase 1 (PINK1) gene cause an autosomal recessive form of Parkinson disease
(PD). So far, no substrates of PINK1 have been reported, and the mechanism by which PINK1 mutations lead to
neurodegeneration is unknown. Here we report the identification of TNF receptor-associated protein 1 (TRAP1), a
mitochondrial molecular chaperone also known as heat shock protein 75 (Hsp75), as a cellular substrate for PINK1
kinase. PINK1 binds and colocalizes with TRAP1 in the mitochondria and phosphorylates TRAP1 both in vitro and in
vivo. We show that PINK1 protects against oxidative-stress-induced cell death by suppressing cytochrome c release
from mitochondria, and this protective action of PINK1 depends on its kinase activity to phosphorylate TRAP1.
Moreover, we find that the ability of PINK1 to promote TRAP1 phosphorylation and cell survival is impaired by PD-
linked PINK1 G309D, L347P, and W437X mutations. Our findings suggest a novel pathway by which PINK1
phosphorylates downstream effector TRAP1 to prevent oxidative-stress-induced apoptosis and implicate the
dysregulation of this mitochondrial pathway in PD pathogenesis.
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Introduction
Parkinson disease (PD) is the second most common
neurodegenerative disease, characterized by the selective loss
of dopaminergic neurons in the substantia nigra [1]. The
cause of PD, particularly the sporadic disease, is unclear, but
it likely involves both genetic and environmental factors.
Genetic studies have identiﬁed a number of genes associated
with familial PD [2]. Postmortem analyses reveal a deﬁciency
in the mitochondrial complex I function in patients with
sporadic PD [3]. Furthermore, exposure to environmental
toxins that inhibit the mitochondrial complex I can lead to
PD-like phenotypes in animal models [4], suggesting the
involvement of mitochondrial dysfunction in PD patho-
genesis.
Mutations in the PTEN induced putative kinase 1 (PINK1) gene
were originally discovered in three pedigrees with recessively
inherited PD. Two homozygous PINK1 mutations were
initially identiﬁed: a truncating nonsense mutation (W437X)
and a G309D missense mutation [5]. Subsequently, multiple
additional types of PD-linked mutations or truncations in
PINK1 have been reported, making PINK1 the second most
common causative gene of recessive PD [6,7]. Interestingly,
despite autosomal recessive transmission of PINK1-linked
early-onset PD, a number of heterozygous mutations affecting
only one PINK1 allele have been associated with late-onset PD
[6–10]. The pathogenic mechanisms by which PINK1 muta-
tions lead to neurodegeneration are unknown.
PINK1 encodes a 581-amino-acid protein with a predicted
N-terminal mitochondrial targeting sequence and a con-
served serine/threonine kinase domain [5]. PINK1 protein has
been shown to localize in the mitochondria [5,11–13] and
exhibit autophosphorylation activity in vitro [11,12,14]. The
in vivo substrate(s) and biochemical function of PINK1
remain unknown. In cultured mammalian cells, overexpres-
sion of wild-type PINK1 protects cells against apoptotic
stimuli [5,15], whereas small interfering RNA (siRNA)–
mediated depletion of PINK1 increases the susceptibility to
apoptotic cell death [16]. In Drosophila, loss of PINK1 leads to
mitochondrial defects and degeneration of muscle and
dopaminergic neurons [17–20]. Despite ample evidence
indicating an essential role of PINK1 in cytoprotection, the
mechanism by which PINK1 protects against apoptosis is not
understood.
Here, we describe the characterization of mitochondrial
serine/threonine kinase PINK1 and report the identiﬁcation
of TNF receptor-associated protein 1 (TRAP1), a mitochon-
drial molecular chaperone also known as heat shock protein
75 (Hsp75), as a PINK1 substrate. Our results suggest that
PINK1 protects against oxidative-stress-induced apoptosis by
phosphorylating downstream effector TRAP1, and provide
novel insights into the pathogenic mechanisms of PINK1
mutations in causing PD.
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PINK1 Interacts with TRAP1
To identify PINK1-interacting proteins, we performed
afﬁnity puriﬁcation experiments using anti-FLAG M2 afﬁnity
gel to isolate proteins associated with C-terminally FLAG-
tagged human wild-type PINK1 from transfected HeLa cell
extracts. Consistent with previous reports [11,12], Western
blot analysis detected a 63-kDa full-length form (PINK1f) and
a 52-kDa processed form (PINK1p) of PINK1 protein in the
cell extracts (Figure 1A, ‘‘Input’’). Both forms of PINK1 were
eluted from the afﬁnity column in fractions 3 and 4 (Figure
1A). Ponceau S staining of the afﬁnity-puriﬁed PINK1
immune complexes revealed the presence of several proteins
that were speciﬁcally associated with PINK1 (Figure 1B). Mass
spectrometry analysis unambiguously identiﬁed the 75-kDa
PINK1-associated protein as TRAP1, a ubiquitously expressed
protein with signiﬁcant sequence homology to the
HSP90AA1 family of molecular chaperones [21–23].
In order to characterize endogenous PINK1 protein and its
interaction with TRAP1, we generated a rabbit polyclonal
anti-PINK1 antibody against amino acid residues 135–155 of
human PINK1. Western blot analysis demonstrated that the
anti-PINK1 antibody, but not the preimmune serum, specif-
ically recognized endogenous PINK1 as well as recombinant
wild-type and mutant PINK1 proteins (Figure 1C; additional
data not shown). Using this anti-PINK1 antibody, we found
that both the full-length and the processed forms of
endogenous PINK1 co-immunoprecipitated with TRAP1 in
PC12 cells (Figure 1D), conﬁrming that the identiﬁed PINK1–
TRAP1 interaction occurs in vivo. We then assessed the
interaction of TRAP1 with PD-linked PINK1 mutants (G309D,
W437X, and L347P) and with putative catalytically inactive
PINK1 mutants (K219A, D362A, D384A, and the triple
mutant K219A/D362A/D384A [KDD]). None of the PINK1
mutations examined had any signiﬁcant effect on the ability
of PINK1 to bind TRAP1 (Figure 1E).
PINK1 Colocalizes with TRAP1 in the Mitochondria
Next, we analyzed the intracellular distribution and
colocalization of PINK1 and TRAP1 by using immunoﬂuor-
escence confocal microscopy. PINK1 and TRAP1 both
contain a predicted mitochondria targeting signal at their
N-terminus, and a mitochondrial localization has previously
been reported for PINK1 [12] as well as for TRAP1 [23]. In
agreement with the earlier studies, we found that both PINK1
and TRAP1 proteins are localized to the mitochondria
labeled by MitoTracker (Figure S1). Moreover, double label-
ing immunocytochemistry analysis revealed a substantial
overlap between PINK1 and TRAP1 staining (Figure S1),
suggesting that these two proteins colocalize in the mito-
chondria.
To complement our immunocytochemistry data, we used
subcellular fractionation to characterize the intracellular
distribution of PINK1 and TRAP1. Western blot analysis
showed a clear co-fractionation of endogenous PINK1 and
TRAP1 on a 5%–15% linear Optiprep gradient with
mitochondria marker TIMM23, but not with endoplasmic
reticulum marker CANX (Figure 2A). Further fractionation
studies of the isolated mitochondria revealed that endoge-
nous PINK1 and TRAP1 were both primarily found in the
mitochondrial inner membrane and intermembrane space
fractions (Figure 2B). Together, these results provide strong
support for an in vivo association of PINK1 with TRAP1 in
the mitochondria. Similar analyses of PC12 cells expressing
wild-type PINK1 or PD-linked G309D, W437X, and L347P
mutant PINK1 showed that the mitochondrial colocalization
of PINK1 with TRAP1 was not affected by the pathogenic
PINK1 mutations (Figure S2).
PINK1 Phosphorylates TRAP1, and the Kinase Activity Is
Abrogated by PD-linked Mutations
Our ﬁnding of a speciﬁc interaction and colocalization
between TRAP1 and PINK1 raises the possibility that TRAP1
may be a substrate of PINK1 kinase. To examine this
possibility, we performed in vitro kinase assays to investigate
the ability of wild-type and mutant PINK1 to phosphorylate
TRAP1. We observed a robust phosphorylation of TRAP1 by
wild-type PINK1, as shown by the PINK1-mediated transfer of
32P from [c-
32P] ATP to the TRAP1 protein (Figure 3A).
Computer modeling analysis of the PINK1 kinase domain
suggests that the amino acid residues K219, D362, and D384
might be key determinants of PINK1 catalytic activity [11]. To
test this prediction, we assessed the effects of single or triple
mutations of these residues to alanines (K219A, D362A,
D384A, or KDD) on the kinase activity of PINK1 in
phosphorylating TRAP1. Although K219A mutation had no
signiﬁcant effect on the PINK1 kinase activity, the D362A,
D384A, and KDD triple mutations dramatically reduced
PINK1 activity in phosphorylating TRAP1 (Figure 3A and
3B). Analysis of the effects of PD-linked PINK1 mutations on
the in vitro phosphorylation of TRAP1 revealed that the
pathogenic mutation G309D or L347P virtually abolished the
kinase activity of PINK1. In contrast, the kinase activity of
PINK1 was not signiﬁcantly affected by the W437X mutation
(Figure 3A and 3B).
We next examined the effects of overexpressing wild-type
or mutant PINK1 on the in vivo phosphorylation of
endogenous TRAP1 in PC12 cells. As shown in Figure 3C,
we observed a low basal level of TRAP1 phosphorylation in
untransfected PC12 cells. TRAP1 phosphorylation was sig-
niﬁcantly increased in response to oxidative stress induced by
H2O2. Overexpression of wild-type PINK1 resulted in a 3.3-
fold increase in the basal level of TRAP1 phosphorylation and
PLoS Biology | www.plosbiology.org July 2007 | Volume 5 | Issue 7 | e172 1495
PINK1 Phosphorylates TRAP1
Author Summary
Parkinson disease (PD) is characterized by the selective loss of
midbrain dopaminergic neurons. Although the cause of PD is
unknown, pathological analyses have suggested the involvement of
oxidative stress and mitochondrial dysfunction. Recently, an
inherited form of early-onset PD has been linked to mutations in
both copies of the gene encoding the mitochondrial protein PINK1.
Furthermore, increasing evidence indicates that single-copy muta-
tions in PINK1 are a significant risk factor in the development of
later-onset PD. Here we show that PINK1 is a protein kinase that
phosphorylates the mitochondrial molecular chaperone TRAP1 to
promote cell survival. We find that PINK1 normally protects against
oxidative-stress-induced cell death by suppressing cytochrome c
release from mitochondria. The PINK1 mutations linked to PD impair
the ability of PINK1 to phosphorylate TRAP1 and promote cell
survival. Our findings reveal a novel anti-apoptotic signaling
pathway that is disrupted by mutations in PINK1. We suggest that
this pathway has a role in PD pathogenesis and may be a target for
therapeutic intervention.a 2.2-fold increase in oxidative-stress-induced TRAP1 phos-
phorylation (Figure 3C and 3D). The ability of PINK1 to
promote in vivo TRAP1 phosphorylation was abolished by the
PD-linked PINK1 mutations G309D and L347P. In fact, cells
overexpressing G309D or L347P mutant PINK1 had approx-
imately 50% lower levels of both basal and oxidative-stress-
induced TRAP1 phosphorylation than the untransfected cells
(Figure 3C and 3D). Since G309D and L347P mutations did
not alter the interaction or colocalization of PINK1 with
TRAP1 (Figures 1 and S2), our results suggest that these
pathogenic PINK1 mutants have a dominant negative effect
on TRAP1 phosphorylation in vivo by competing with
endogenous PINK1 for binding of its substrate TRAP1.
Interestingly, although the W437X mutation had no signiﬁ-
cant effect on PINK1-mediated TRAP1 phosphorylation in
vitro (Figure 3A and 3B), the mutation caused a 30% to 45%
reduction in both basal and oxidative-stress-induced levels of
TRAP1 phosphorylation in vivo compared with wild-type
PINK1 (Figure 3C and 3D). These results suggest that the
W437X mutation has an inhibitory effect on the kinase
activity of PINK1 in phosphorylating TRAP1 in vivo.
PINK1 Protects against Oxidative-Stress-Induced Cell
Death, and the Protective Action Depends on Its Kinase
Activity
Given the observed effects of PINK1 on oxidative-stress-
induced phosphorylation of TRAP1 (Figure 3), we inves-
tigated the roles of wild-type and mutant PINK1 proteins in
cell vulnerability to oxidative stress. PC12 cells were trans-
fected with C-terminally FLAG-tagged wild-type or mutant
PINK1 to achieve similar levels of exogenous PINK1 protein
expression, as conﬁrmed by Western blot analysis (data not
shown). Cell viability assays revealed that treatment of
Figure 2. PINK1 and TRAP1 Colocalize in the Mitochondrial Inner
Membrane and the Intermembrane Space
(A) Post-nuclear supernatants of PC12 cells were fractionated on a 5%–
15% linear Optiprep gradient, and the fractions were analyzed by
immunoblotting for PINK1, TRAP1, TIMM23, and CANX.
(B) Mitochondria (Mito) isolated from PC12 cells were fractionated into
matrix, inner mitochondrial membrane (IM), intermembrane space (IMS),
and outer mitochondrial membrane (OM) fractions, and analyzed by
immunoblotting for PINK1, TRAP1, and markers of mitochondrial
subcompartments: HSPD1 (matrix), TIMM23 (IM), cytochrome c (IMS),
and VDAC (OM).
doi:10.1371/journal.pbio.0050172.g002
Figure 1. Interaction of TRAP1 with Wild-Type and Mutant PINK1
(A) Lysates of HeLa cells expressing C-terminally FLAG-tagged wild-type
PINK1 (Input) were affinity purified with anti-FLAG M2 affinity gel, and
the eluate fractions were analyzed by immunoblotting with anti-FLAG
antibody.
(B) Affinity-purified proteins from PINK1-transfected cells and vector
control were resolved on SDS-PAGE and detected by Ponceau S staining.
Arrows indicate three bands identified by mass spectrometry as TRAP1,
PINK1f, and PINK1p.
(C) Specificity of the polyclonal anti-PINK1 antibody. Homogenates (50
lg of protein per lane) from rat brain, liver, untransfected PC12 cells, and
transfected PC12 cells expressing wild-type (WT) or mutant PINK1 were
analyzed by immunoblotting with anti-PINK1 and anti-actin antibodies.
(D) Endogenous PINK1 interacts with TRAP1. PC12 cell lysates (Input)
were immunoprecipitated with anti-TRAP1 antibody, followed by
immunoblotting with anti-PINK1 and anti-TRAP1 antibodies. IgG HC,
IgG heavy chain.
(E) Lysates from PC12 cells transfected with FLAG-tagged wild-type or
mutant PINK1 were immunoprecipitated with anti-FLAG antibody,
followed by immunoblotting using anti-TRAP1 and anti-FLAG antibodies.
doi:10.1371/journal.pbio.0050172.g001
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PINK1 Phosphorylates TRAP1untransfected or vector-transfected PC12 cells with H2O2
resulted in cell death (Figure 4A; and additional data not
shown). Cells expressing exogenous wild-type PINK1 were
much more resistant to H2O2-induced cell death (Figure 4A),
supporting a protective role of PINK1 against oxidative
stress. The protective effect of PINK1 was signiﬁcantly
decreased by the putative kinase-dead K219A mutation and
was completely abolished by the catalytically inactive D362A,
D384A, and KDD triple mutations (Figure 4A), indicating that
the cytoprotective function of PINK1 depends on its kinase
activity.
Analysis of the effects of PD-linked PINK1 mutations on
cell vulnerability revealed that the pathogenic W437X
mutation signiﬁcantly reduced the ability of PINK1 to protect
against oxidative-stress-induced cell death (Figure 4A). We
found that the pathogenic G309D and L347P mutations not
only abolished the cytoprotective effect of PINK1, but also
exacerbated oxidative-stress-induced cell death (Figure 4A),
suggesting a dominant negative effect of these mutations on
cell survival.
PINK1 Prevents Oxidative-Stress-Induced Cell Death by
Suppressing Cytochrome c Release from Mitochondria
The observed mitochondrial localization (Figure 2) and
cytoprotective action (Figure 4A) of PINK1 raise the
possibility that PINK1 may regulate the mitochondrial cell
death pathway. To test this possibility, we examined the
effects of overexpressing wild-type and mutant PINK1
proteins on the release of cytochrome c from mitochondria,
a crucial step in the mitochondrial apoptotic cascade. As
shown in Figure 4B, treatment of vector-transfected PC12
cells with H2O2 induced cytochrome c release from mito-
chondria to the cytosol in a time-dependent manner. Over-
expression of wild-type PINK1 caused a signiﬁcant reduction
in the release of cytochrome c under the same oxidative stress
conditions (Figure 4B and 4C). The inhibitory effect of PINK1
on cytochrome c release was completely abrogated by the
catalytically inactive D362A mutation and the KDD triple
mutations (Figure 4B and 4C), suggesting the critical involve-
ment of PINK1 kinase activity in regulation of mitochondrial
apoptotic pathway.
Analysis of the effects of PD-linked PINK1 mutations on
cytochrome c release showed that the W437X mutation
caused a signiﬁcant increase in H2O2-induced cytochrome c
release compared to cells expressing similar level of exoge-
nous wild-type PINK1 (Figure 4B and 4C), in agreement with
the observed effect of the W437X mutation on the cytopro-
tective function of PINK1 (Figure 4A). The pathogenic G309D
and L347P mutations not only abolished the ability of PINK1
to suppress cytochrome c release, but also accelerated H2O2-
induced cytochrome c release (Figure 4B and 4C), consistent
with the dominant negative effects of these mutations on cell
survival (Figure 4A). Western blot analysis conﬁrmed that the
relative distribution of PINK1 in the mitochondria and
cytosol fractions was not altered by the H2O2 treatment or by
the PINK1 mutations examined (data not shown), suggesting
that the observed effects of wild-type and mutant PINK1
proteins on cell survival are mediated through their action in
mitochondria on the release of cytochrome c rather than by
altering the subcellular localization of PINK1.
PINK1 Is Essential for Phosphorylation of TRAP1 and
Protection against Oxidative-Stress-Induced Apoptosis
To provide further evidence supporting the role of PINK1
in regulation of TRAP1 phosphorylation and mitochondrial
apoptotic signaling, we examined the effect of siRNA-
Figure 3. Phosphorylation of TRAP1 by Wild-Type and Mutant PINK1
(A) In vitro kinase assays were performed by incubation of purified TRAP1
with [c
32-P] ATP in the absence (control) or presence of FLAG-tagged
wild-type (WT) or mutant PINK1 proteins as indicated. Phosphorylated
TRAP1 was visualized by autoradiography (top panel). PINK1 and TRAP1
proteins used in the kinase assays were shown by immunoblotting with
anti-TRAP1 (middle panel) and anti-FLAG antibodies (bottom panel).
(B) Normalized levels of in vitro TRAP1 phosphorylation by wild-type or
mutant PINK1. Data represent mean 6 standard error of the mean (SEM)
from three independent experiments.
*Significantly different from the
wild-type PINK1 (p , 0.01).
(C) PC12 cells expressing wild-type or mutant PINK1 or vector-
transfected controls were treated with 400 lMH 2O2 as indicated. In
vivo phosphorylation of endogenous TRAP1 was determined by
immunoprecipitation with anti-TRAP1 antibody followed by immuno-
blotting using anti-phosphoserine (upper panel) and anti-TRAP1 (lower
panel) antibodies.
(D) Normalized levels of in vivo TRAP1 phosphorylation by wild-type or
mutant PINK1. Data represent mean 6 SEM from three independent
experiments.
aSignificantly different from the corresponding H2O2-
treated vector-transfected controls (p , 0.01).
bSignificantly different
from the wild-type PINK1-transfected cells (p , 0.01).
AU, arbitrary units.
doi:10.1371/journal.pbio.0050172.g003
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PINK1 Phosphorylates TRAP1mediated PINK1 knockdown on TRAP1 phosphorylation and
oxidative-stress-induced apoptosis. As shown in Figure 5A,
PINK1 siRNA-1 and PINK1 siRNA-2, two distinct siRNA
duplexes targeting different regions of PINK1 mRNA, both
speciﬁcally inhibited the expression of endogenous PINK1 in
PC12 cells. We found that, in cells transfected with either
PINK1 siRNA-1 or PINK1 siRNA-2, H2O2-induced phosphor-
ylation of endogenous TRAP1 was signiﬁcantly decreased
compared with the cells transfected with non-targeting (NT)
control siRNA or with vehicle alone (Figure 5B and 5C). These
results further conﬁrm that TRAP1 is indeed a substrate of
PINK1 kinase.
Cell viability and nuclear morphology analyses revealed
that depletion of endogenous PINK1 by PINK1 siRNA-1 or
PINK1 siRNA-2 enhanced the susceptibility of PC12 cells to
oxidative-stress-induced apoptosis (Figure 5D–5F). Moreover,
PINK1 depletion signiﬁcantly increased oxidative-stress-
induced release of cytochrome c from mitochondria to the
cytosol (Figure 6). Together, these data provide strong
support for a critical role of PINK1 in regulation of the
mitochondrial apoptotic pathway.
TRAP1 Is Required for PINK1-Mediated Protection against
Oxidative-Stress-Induced Apoptosis
Our ﬁnding that TRAP1 phosphorylation by PINK1
correlates with the anti-apoptotic activity of PINK1 raises
the possibility that TRAP1 may be the intermediate between
PINK1 and apoptosis inhibition. To test this possibility, we
investigated the effect of siRNA-mediated TRAP1 knockdown
on the cytoprotective function of PINK1. Two different
TRAP1-targeting siRNAs (TRAP1 siRNA-1 and TRAP1
siRNA-2) were used to reduce the expression of endogenous
TRAP1 in PC12 cells. Western blot analysis showed that
TRAP1 siRNA-2 caused a greater decrease in TRAP1 protein
level than TRAP1 siRNA-1, whereas the NT control siRNA
had no effect on TRAP1 expression (Figure 7A). Analyses of
cell viability, nuclear morphology, and cytochrome c release
revealed that TRAP1 depletion resulted in a signiﬁcant
increase in oxidative-stress-induced cytochrome c release
and cell death (Figure 7B–7F). We found that, in contrast to
the protective effect of overexpressing wild-type PINK1 seen
in the control (Figure 4) or in the NT siRNA-treated PC12
cells (Figure 7), overexpression of wild-type PINK1 in TRAP1-
depleted PC12 cells was no longer able to inhibit oxidative-
stress-induced cytochrome c release and cell death (Figure
7B–7F). Moreover, the dominant negative effects on cell
survival observed with PD-linked G309D and L347P mutant
PINK1 (Figure 4) were also abolished by TRAP1 depletion
(Figure 7B–7F). Taken together, these results provide evi-
dence supporting a role of TRAP1 as the downstream effector
of PINK1 in protection against oxidative-stress-induced
apoptosis.
Given our result that TRAP1 is localized in the mitochon-
drial inner membrane and the intermembrane space where
cytochrome c is located (Figure 2B), we next investigated
whether TRAP1 may exert its anti-apoptotic function by
binding directly to cytochrome c, thereby preventing it from
being released from mitochondria. Co-immunoprecipitation
experiments failed to ﬁnd TRAP1 in physical association with
cytochrome c either in the absence or presence of wild-type
or mutant PINK1 or under conditions of oxidative stress
(Figure S3), arguing against the possibility that TRAP1-
mediated inhibition of cytochrome c release occurs through
a direct interaction/retention mechanism.
Discussion
Although mutations in the putative kinase PINK1 are a
common cause of autosomal recessive PD, very little is known
about the biological function of PINK1 and how loss of
Figure 4. Wild-Type PINK1, but Not Kinase-Dead or PD-Linked Mutant PINK1, Protects against Oxidative-Stress-Induced Apoptosis
(A) PC12 cells expressing wild-type (WT) or mutant PINK1 or vector-transfected controls were treated with 400 lMH 2O2 for 16 h. The extent of cell
survival was assessed by using the MTT assay. Data represent mean 6 SEM from three independent experiments.
aSignificantly different from the
vector-transfected controls (p , 0.01).
bSignificantly different from the wild-type PINK1-transfected cells (p , 0.01).
(B) Immunoblot analysis of cytochrome c (Cyt. c) in the cytosol and mitochondria fractions isolated from PC12 cells expressing wild-type or mutant
PINK1 after treatment with 400 lMH 2O2 for the indicated times.
(C) The level of cytochrome c released to the cytosol is normalized to the total level of cytochrome c in each cell sample. Data represent mean 6 SEM
from three independent experiments.
aSignificantly different from the corresponding H2O2-treated vector-transfected controls (p , 0.01).
bSignificantly
different from the wild-type PINK1-transfected cells (p , 0.01).
doi:10.1371/journal.pbio.0050172.g004
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PINK1 Phosphorylates TRAP1PINK1 function leads to neurodegeneration. The present
study demonstrates that PINK1 is a mitochondrial serine/
threonine kinase with a critical role in promoting cell
survival. We have identiﬁed what is to our knowledge the
ﬁrst substrate for the PINK1 kinase: the mitochondrial
molecular chaperone TRAP1. Our ﬁndings reveal a hitherto
unexplored pathway by which PINK1 phosphorylates down-
stream effector TRAP1 to protect cells against apoptosis, and
suggest a link between the impairment of this novel
mitochondrial pathway and neurodegeneration in PD.
It has become increasingly clear that molecular chaperones
not only facilitate protein folding, but also regulate a number
Figure 5. PINK1 Knockdown Reduces TRAP1 Phosphorylation and
Protection against Oxidative Stress
(A) PC12 cells were transfected with vehicle (control), NT siRNA, or PINK1-
specific siRNAs (PINK1 siRNA-1 and PINK1 siRNA-2). The levels of PINK1
and actin in the cell lysates were analyzed by immunoblotting with anti-
PINK1 and anti-actin antibodies.
(B) PC12 cells transfected with the indicated siRNA or vehicle (control)
were treated with 400 lMH 2O2 for the indicated times. In vivo
phosphorylation of endogenous TRAP1 was determined by immuno-
precipitation with anti-TRAP1 antibody followed by immunoblotting
using anti-phosphoserine and anti-TRAP1 antibodies.
(C) Normalized levels of in vivo TRAP1 phosphorylation in the control and
siRNA-transfected cells. Data represent mean 6 SEM from three
independent experiments.
*Significantly different from the correspond-
ing H2O2-treated control cells (p , 0.01). AU, arbitrary units.
(D) PC12 cells transfected with vehicle (control) or the indicated siRNAs
were treated with 400 lMH 2O2 for 16 h. Cell viability was assessed by
using the MTT assay. Data represent mean 6 SEM from three
independent experiments.
*Significantly different from the H2O2-treated
control cells (p , 0.01).
(E) PC12 cells co-transfected with an expression vector encoding
enhanced green fluorescent protein (pEGFP) and vehicle (control) or
indicated siRNAs were treated with 400 lMH 2O2 for 16 h. Transfected
cells were shown by the green fluorescence emitted by green
fluorescent protein (GFP), and nuclear morphology was visualized by
DAPI staining (blue). Arrowheads indicate transfected cells with
apoptotic nuclei. Scale bar, 10 lm.
(F) Apoptosis is expressed as the percentage of transfected cells with
apoptotic nuclear morphology. Data represent mean 6 SEM from three
independent experiments.
*Significantly different from the H2O2-treated
control cells (p , 0.01).
doi:10.1371/journal.pbio.0050172.g005
Figure 6. PINK1 Depletion Increases Cytochrome c Release from
Mitochondria
(A) PC12 cells transfected with the indicated siRNA or vehicle (control)
were treated with 400 lMH 2O2 for the indicated times. The levels of
cytochrome c (Cyt. c) and actin in the cytosol were determined by
immunoblotting with anti-cytochrome c and anti-actin antibodies.
(B) The level of cytochrome c released to the cytosol is normalized to the
level of actin in each cell sample. Data represent mean 6 SEM from three
independent experiments.
*Significantly different from the correspond-
ing H2O2-treated control cells (p , 0.01). AU, arbitrary units.
(C) PC12 cells co-transfected with pEGFP and vehicle (control) or
indicated siRNAs were treated with 400 lMH 2O2 for 16 h. Cell
morphology was imaged by using phase-contrast microscopy (grey),
transfected cells were visualized by the green fluorescence emitted by
green fluorescent protein (GFP), and the cellular distribution of
cytochrome c was detected by immunostaining with anti-cytochrome
c antibody (red). Transfected cells with mitochondrial cytochrome c
staining are indicated by arrows, and those with diffuse, cytosolic
cytochrome c staining are indicated by arrowheads. Scale bar, 10 lm.
(D) Quantification of the percentage of transfected cells showing
cytochrome c release. Data represent mean 6 SEM from three
independent experiments.
*Significantly different from the H2O2-treated
control cells (p , 0.05).
doi:10.1371/journal.pbio.0050172.g006
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PINK1 Phosphorylates TRAP1of cellular processes, including cell survival and apoptosis
[24,25]. Despite the critical importance of mitochondria in
cell function and survival, the current knowledge about
mitochondrial molecular chaperones is limited. TRAP1 is a
poorly characterized mitochondrial protein with signiﬁcant
sequence homology to the HSP90AA1 family of molecular
chaperones [23]. Our ﬁnding that siRNA-mediated depletion
of TRAP1 sensitizes cells to oxidative-stress-induced cyto-
chrome c release and cell death suggests a role for TRAP1 in
the modulation of the mitochondrial apoptotic cascade.
Consistent with this role, TRAP1 knockdown has been shown
to enhance cytochrome c release and apoptosis induced by
other stressors, such as protein-tyrosine kinase inhibitor b-
hydroxyisovalerylshikonin and topoisomerase II inhibitor
VP16 [26]. The molecular basis of the anti-apoptotic function
of TRAP1 remains unknown. Although we ﬁnd that TRAP1
and cytochrome c colocalize in the mitochondrial intermem-
brane space, our results indicate that TRAP1 does not
physically associate with cytochrome c in cells either in the
absence or presence of oxidative stress. Thus, TRAP1 may
inhibit the release of cytochrome c from mitochondria
through a mechanism other than direct interaction/retention.
Future studies are required to elucidate the mechanism by
which TRAP1 regulates cytochrome c release and apoptosis.
Our data reveal that endogenous TRAP1 is constitutively
phosphorylated at low levels, and the TRAP1 phosphorylation
Figure 7. TRAP1 Depletion Abolishes the Effects of Wild-Type and Mutant PINK1 on Cell Vulnerability to Oxidative Stress
(A) PC12 cells were transfected with vehicle (control), NT siRNA, or TRAP1-specific siRNAs (TRAP1 siRNA-1 and TRAP1 siRNA-2). The levels of TRAP1 and
actin in the cell lysates were analyzed by immunoblotting with anti-TRAP1 and anti-actin antibodies.
(B) PC12 cells treated with TRAP1 siRNA-2 or NT siRNA were either untransfected (UT) or transfected with wild-type (WT) or mutant PINK1 as indicated.
Vehicle-treated, non-transfected PC12 cells were used as the control. Cells were exposed to 400 lMH 2O2 for 16 h, and the extent of cell survival was
assessed by using the MTT assay. Data represent mean 6 SEM from three independent experiments. *, p , 0.05; ns, not significant.
(C) PC12 cells co-transfected with pEGFP and vehicle (control) or indicated siRNAs and PINK1 plasmids were treated with 400 lMH 2O2 for 16 h, and the
extent of apoptosis was determined by morphological analysis of DAPI-stained nuclei. The percentage of transfected cells with apoptotic nuclear
morphology was quantified. Data represent mean 6 SEM from three independent experiments.
*, p , 0.05; ns, not significant.
(D) The levels of cytochrome c (Cyt. c) and actin in the cytosol fractions from cells described in (B) were determined by immunoblotting with anti-
cytochrome c and anti-actin antibodies.
(E) The level of cytochrome c released to the cytosol is normalized to the level of actin in each cell sample. Data represent mean 6 SEM from three
independent experiments.
*, p , 0.01; ns, not significant. AU, arbitrary units.
(F) PC12 cells co-transfected with pEGFP and vehicle (control) or indicated siRNAs and PINK1 plasmids were treated with 400 lMH 2O2 for 16 h, and the
cellular distribution of cytochrome c was detected by immunostaining with anti-cytochrome c antibody. The percentage of transfected cells showing
cytochrome c release was quantified. Data represent mean 6 SEM from three independent experiments.
*, p , 0.05; ns, not significant.
doi:10.1371/journal.pbio.0050172.g007
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induced by H2O2. Both constitutive and oxidative-stress-
induced TRAP1 phosphorylation are dramatically enhanced
by PINK1 overexpression and are reduced by siRNA-
mediated depletion of PINK1, indicating that PINK1 is a
major kinase responsible for phosphorylating TRAP1 in cells.
These results, together with the in vitro phosphorylation data,
provide compelling evidence that TRAP1 is a bona ﬁde
substrate for PINK1 kinase. We ﬁnd that overexpression of
PINK1 protects cells against oxidative-stress-induced apop-
tosis by suppressing cytochrome c release from mitochondria,
and this protective action of PINK1 depends on its kinase
activity to phosphorylate TRAP1. Conversely, PINK1 deple-
tion causes increased cytochrome c release from mitochon-
dria and sensitizes cells to oxidative-stress-induced cell death,
and the pro-apoptotic effect of PINK1 depletion correlates
with reduced TRAP1 phosphorylation. Moreover, our studies
using TRAP1 siRNAs have provided direct evidence that
TRAP1 is required for PINK1-mediated protection against
oxidative-stress-induced cytochrome c release and cell death.
Collectively, these ﬁndings point to a speciﬁc pathway in
which PINK1 exerts its cytoprotective function by phosphor-
ylating downstream effector TRAP1 to inhibit the release of
cytochrome c from mitochondria.
Our work indicates that the mitochondrial PINK1–TRAP1
anti-apoptotic pathway is disrupted by PD-linked PINK1
G309D, L347P, and W437X mutations. Previous studies of
PINK1 mutations using in vitro autophosphorylation assays
and artiﬁcial kinase substrates have led to conﬂicting results.
For example, analyses with recombinant GST-fused PINK1
proteins puriﬁed from Escherichia coli showed that PINK1
autophosphorylation activity was slightly decreased by the
G309D mutation [11,12] and was signiﬁcantly increased by the
W437X mutation [12] and that neither of these mutations
affected the activity of PINK1 to phosphorylate artiﬁcial
substrate a-casein [12]. In contrast, a recent study using
recombinant PINK1 proteins isolated from baculovirus-
infected sf9 insect cells failed to detect PINK1 autophosphor-
ylation activity, but showed that PINK1 C-terminal trunca-
tion reduced the activity of PINK1 to phosphorylate artiﬁcial
substrate histone H1 [27]. These discrepancies underscore the
importance of knowing physiological substrate(s) for charac-
terizing the kinase function of wild-type and mutant PINK1.
Our analyses reveal that single G309D and L347P mutations
abolish the kinase activity of PINK1 to phosphorylate its
physiological substrate TRAP1 both in vitro and in vivo. By
comparison, the W437X mutation has a weaker effect on
PINK1-mediated TRAP1 phosphorylation. Our ﬁndings that
PD-linked mutations impair the ability of PINK1 to promote
TRAP1 phosphorylation and cell survival provide strong
support for a loss-of-function pathogenic mechanism in
familial PD patients carrying homozygous PINK1 mutations.
Recently, an increasing number of PD cases with hetero-
zygous mutations affecting only one PINK1 allele have been
reported, including single heterozygous G309D and W437X
mutations [6–10]. Our results that PD-linked PINK1 muta-
tions speciﬁcally inhibit PINK1 kinase function without
affecting the substrate binding or subcellular localization of
PINK1 raise an interesting possibility that these mutants may
act in a dominant negative manner to inhibit the function of
the normal PINK1 allele by competing with endogenous wild-
type PINK1 for binding its substrate TRAP1. In support of
this possibility, we ﬁnd that PD-linked PINK1 G309D and
L347P mutations have a dominant negative effect on in vivo
TRAP1 phosphorylation and cell survival. These results
suggest a dominant negative pathogenic mechanism by which
heterozygous PINK1 mutations lead to Parkinsonian symp-
toms [6,7,9]. By comparison, overexpression studies show that
the W437X mutation has a smaller but signiﬁcant inhibitory
effect on in vivo TRAP1 phosphorylation and cell survival,
providing evidence supporting a pathogenic role of the
heterozygous W437X mutation. Our ﬁnding of a mitochon-
drial PINK1–TRAP1 anti-apoptotic pathway and its impair-
ment by PD-linked mutations provides new insights into the
pathogenic mechanisms of PD and suggests novel targets for
therapeutic intervention.
Materials and Methods
Plasmids and anti-PINK1 antibody. Conventional molecular bio-
logical techniques [28] were used to generate the C-terminally FLAG-
tagged human PINK1 (PINK1-FLAG), the PD-linked G309D, W437X,
and L347P mutant PINK1, and the putative catalytically inactive
PINK1 mutants, K219A, D362A, D384A, and the KDD triple mutant.
A polyclonal anti-PINK1 antibody was raised in rabbit against amino
acids 135–155 of human PINK1, and afﬁnity puriﬁed as described
previously [29].
Afﬁnity puriﬁcation and mass spectrometry. HeLa cells transfected
with pPINK1-FLAG or the vector control were lysed in a buffer
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, and protease inhibitor cocktail (Sigma, http://
www.sigmaaldrich.com). The lysates were afﬁnity puriﬁed with anti-
FLAG M2 afﬁnity gel (Sigma). FLAG-tagged PINK1-protein com-
plexes were eluted into 1-ml fractions and analyzed by immunoblot-
ting with anti-FLAG antibody (Roche Applied Science, http://www.
roche-applied-science.com). The fractions containing FLAG-tagged
PINK1 protein were pooled and resolved on SDS-PAGE. The
proteins were then transferred to PVDF membrane followed by
Ponceau S staining. Protein bands were excised from the membrane,
digested by trypsin, and analyzed by nanoelectrospray tandem mass
spectrometry as described previously [30,31].
Cell transfections and immunoprecipitations. HeLa and PC12 cells
were transfected with the indicated plasmids by using Lipofectamine
2000 (Invitrogen, http://www.invitrogen.com) and TransIT neuronal
transfection reagent (Mirus, http://www.mirusbio.com), respectively,
according to the manufacturer’s instructions. Immunoprecipitations
were performed at 24 h post-transfection as described [32] using the
indicated antibodies. The immunocomplexes were resolved by SDS-
PAGE and analyzed by immunoblotting [32].
In vitro and in vivo phosphorylation assays. In vitro kinase assays
were performed as described [33] by incubation of afﬁnity-puriﬁed
FLAG-tagged wild-type or mutant PINK1 with TRAP1 for 20 min at
30 8C in 100 ll of reaction buffer containing 50 mM Tris-HCl (pH
7.5), 8 mM MgCl2, 2 mM MnCl2, 0.1 mM ATP, and 5 lCi of [c-32P]
ATP. The reaction mixtures were resolved by SDS-PAGE, and
phosphorylated TRAP1 was visualized by autoradiography. The
relative level of in vitro TRAP1 phosphorylation was measured by
quantifying the amount of
32P incorporated into TRAP1 and was
normalized against the level of total TRAP1. For detection of in vivo
phosphorylation of TRAP1, endogenous TRAP1 protein was immu-
noprecipitated by using anti-TRAP1 antibody (BD Biosciences, http://
www.bdbiosciences.com), followed by immunoblotting with anti-
phosphoserine antibody (Invitrogen). The relative level of in vivo
TRAP1 phosphorylation was determined by measuring the intensity
of the phosphoserine-immunoreactive band and was normalized
against the level of total TRAP1.
Immunoﬂuorescence confocal microscopy. Double labeling indi-
rect immunoﬂuorescence microscopy was performed as described
previously [29,34,35]. Mitochondria were labeled with MitoTracker
(Molecular Probes, http://probes.invitrogen.com) prior to ﬁxation.
Cells were then immunostained with the indicated antibodies, and
examined by using a Zeiss (http://www.zeiss.com) LSM 510 confocal
microscope.
Subcellular fractionations. For separation of mitochondria and
other organelles, PC12 cells were homogenized and fractionated on a
5%–15% linear Optiprep (Nycomed, http://www.nycomed.com) gra-
dient as described previously [32]. For sub-mitochondria fractiona-
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by differential centrifugation into the matrix, the inner mitochon-
drial membrane, the intermembrane space, and the outer mitochon-
drial membrane fractions as described [36].
siRNA transfection. For depletion of PINK1 or TRAP1 in PC12
cells, siRNAs (Dharmacon, http://www.dharmacon.com) were gener-
ated against the following rat PINK1 or TRAP1 mRNA sequences:
PINK1 siRNA-1, 59-CAAGUCCGACAACAUACUU-39; PINK1 siRNA-
2, 59-GCGUGUUGGCCUGCAGUUA-39; TRAP1 siRNA-1, 59-GCAAA-
GAUUUCGCCAACGA-39; and TRAP1 siRNA-2, 59-GAACAUUCACC-
CUAUUAUG-39. A control siRNA with no known mammalian
homology (siCONTROL Non-Targeting siRNA #1, Dharmacon) was
used as negative control. PC12 cells were transfected with the
indicated siRNAs using the TransIT siQUEST (Mirus) reagent as
described previously [37].
Cell viability and apoptosis assays. PC12 cells were treated with
H2O2 as indicated, and cell viability was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
as described [38]. Apoptotic cell death was measured by morpho-
logical assessment of nuclei stained with 49,6-diamidino-2-phenyl-
indole (DAPI, Molecular Probes) as previously described [39]. The
percentage of transfected cells with nuclear shrinkage and chromatin
condensation was scored for apoptosis in a blinded manner.
Cytochrome c release assays. Biochemical assays of cytochrome c
release were performed as described [40]. Brieﬂy, PC12 cells were
homogenized and then fractionated into the mitochondria and
cytosol fractions. The release of cytochrome c from mitochondria to
the cytosol was determined by immunoblotting with anti-cytochrome
c antibody (clone 7H8.2C12, BD Biosciences). For cell-based assays of
cytochrome c release, the cellular distribution of cytochrome c was
determined by immunoﬂuorescence confocal microscopy using anti-
cytochrome c antibody (clone 6H2.B4, BD Biosciences) as described
[41]. The release of cytochrome c from mitochondria to the cytosol
was indicated by a transition from a punctate to a diffuse cytochrome
c immunostaining pattern. The percentage of transfected cells
showing cytochrome c release was scored in a blinded manner.
Statistical analysis. Statistical analysis of the data was performed by
using ANOVA with Tukey’s post hoc analysis.
Supporting Information
Figure S1. Colocalization of PINK1 with TRAP1 in the Mitochondria
Untransfected HeLa cells (D–F) or transfected HeLa cells expressing
PINK1-FLAG (A–C) or PINK1-HA (G–I) were analyzed by double
labeling confocal microscopy with MitoTracker (B and E), anti-FLAG
(A), anti-TRAP1 (D and H), and anti-HA (G) antibodies. Scale bar, 10
lm.
Found at doi:10.1371/journal.pbio.0050172.sg001 (12 MB TIF).
Figure S2. PD-Associated PINK1 Mutations Have No Effect on the
Mitochondrial Colocalization of PINK1 with TRAP1
Mitochondria (Mito) isolated from transfected PC12 cells expressing
wild-type PINK1 or PD-linked G309D, W437X, or L347P mutant
PINK1 were fractionated into matrix, inner mitochondrial mem-
brane (IM), intermembrane space (IMS), and outer mitochondrial
membrane (OM) fractions, and analyzed by immunoblotting for
PINK1 and TRAP1.
Found at doi:10.1371/journal.pbio.0050172.sg002 (1.6 MB TIF).
Figure S3. TRAP1 Does Not Associate with Cytochrome c in the
Absence or Presence of PINK1 and Oxidative Stress
(A) Lysates from untransfected (UT) or transfected PC12 cells
expressing wild-type (WT) PINK1 or the indicated mutant PINK1
were immunoprecipitated with anti-TRAP1 antibody, followed by
immunoblotting using antibodies against TRAP1 and cytochrome c
(Cyt. c). ‘‘Input’’ lane shows the levels of endogenous TRAP1 and
cytochrome c in the lysate of untransfected PC12 cells.
(B) PC12 cells expressing wild-type PINK1 or vector-transfected
controls were incubated in the presence or absence of 400 lMH 2O2
for 16 h. Cell lysates (Input) were subjected to immunoprecipitation
with anti-TRAP1, followed by immunoblotting using antibodies
against TRAP1 and cytochrome c (Cyt. c).
Found at doi:10.1371/journal.pbio.0050172.sg003 (1.2 MB TIF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
ber for TRAP1 is NP_057376.
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